Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. (ATNM) on August 05, 2020. The filing addresses a deficiency letter received from the NYSE American Exchange regarding the Company's compliance with continued listing standards due to sustained low share prices.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and listing status events rather than financial performance data.
Material Changes and Events
- Listing Deficiency: On April 29, 2020, the NYSE American notified the Company of non-compliance with listing standards because its common stock had traded below $1.00 for a substantial period.
- Compliance Deadline: The exchange granted the Company until October 29, 2020, to demonstrate sustained price improvement (trading above $1.00 for 30 consecutive days) or effect a reverse stock split.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the certificate of incorporation on December 18, 2019, authorizing a reverse stock split of up to 1-for-75.
- Implementation Timeline: The Board of Directors has initiated the process to effectuate the reverse split, targeting an effective date in mid-August 2020, subject to necessary approvals.
Outlook, Risks, and Management Commentary
Management indicates that the reverse stock split is the primary mechanism being pursued to regain compliance with NYSE American listing standards. The filing highlights the risk of delisting if the Company fails to either raise the share price above $1.00 for 30 days or successfully implement the reverse split by the October 29, 2020 deadline. No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the exact reverse stock split ratio to be set by the Board of Directors (up to 1-for-75).
- Confirm the official effective date of the reverse stock split, targeted for mid-August 2020.
- Monitor the Company's stock price to ensure it meets the $1.00 threshold for 30 consecutive days if the split is not executed or fails to resolve the deficiency.
- Check for subsequent filings confirming the receipt of necessary regulatory approvals for the reverse split.